We are excited to announce a special call for papers for an upcoming issue of Communications in Transportation Research (COMMTR) that is dedicated to the emerging intersection of generative models and intelligent control in autonomous driving traffic systems.

Major histocompatibility complex class II (MHC-II) molecules play a critical, yet historically overlooked, role in tumor immunity.

Winter arrives with shorter days, colder mornings, and a natural drop in energy. Many men start to feel small physical changes during this season, such as slower digestion, disrupted bowel habits, or a weaker urine stream. These winter symptoms should not be neglected, as some of them are on the checklist of potential cancer symptoms. Advanced genetic testing is reshaping precision oncology, not only for early screening but also for precision treatment. High-throughput sequencing technology-based cancer discovery testing is now helping doctors understand the personal genetic drivers of disease and provide guidance for the most effective treatment solutions, leading to better outcomes.

Researchers at Beijing Tiantan Hospital analyzed 101 glioma cases involving the brain’s motor pathway and found that one-third of patients developed permanent paralysis after surgery. High tumor grade, pre-operative motor deficits, and larger tumor volume were key predictors. The work underscores the need for precise imaging and careful surgical planning to maximize survival while safeguarding motor function.

Alzheimer’s disease (AD) imposes a substantial clinical and societal burden, yet currently approved symptomatic therapies do not modify the underlying disease biology. Recently, three anti-amyloid monoclonal antibodies (aducanumab, lecanemab, and donanemab) have demonstrated robust amyloid clearance. Their clinical effects are statistically significant but modest, underscoring the need for broader, biologically informed strategies. Guided by the 2024 Alzheimer’s association ATNIVS biomarker framework, a team form Xuanwu Hospital, Capital Medical University synthesizes disease-modifying therapies (DMTs) targeting amyloid (A), tau (T), neurodegeneration (N), inflammation (I), vascular injury (V), and α-synuclein (S), summarizing the candidate therapies for each target, explain the mechanisms of action and pivotal clinical trial results. The review is currently published on the journal Medicine Plus.